Translational insights and new therapeutic perspectives in head and neck tumors

Morena Fasano, Francesco Perri, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppina Della Vittoria Scarpati, Marco Cascella, Alessandro Ottaiano, Fortunato Ciardiello, Raffaele Solla

Research output: Contribution to journalReview articlepeer-review


Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists’ community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.

Original languageEnglish
Article number1045
Issue number8
Publication statusPublished - Aug 2021


  • DNA damage response
  • Epithelial growth factor receptor
  • Head and neck squamous cell carcinoma
  • Immunotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Translational insights and new therapeutic perspectives in head and neck tumors'. Together they form a unique fingerprint.

Cite this